Radiomics in colorectal cancer patients
- PMID: 37274803
- PMCID: PMC10237092
- DOI: 10.3748/wjg.v29.i19.2888
Radiomics in colorectal cancer patients
Abstract
The main therapeutic options for colorectal cancer are surgical resection and adjuvant chemotherapy in non-metastatic disease. However, the evaluation of the overall adjuvant chemotherapy benefit in patients with a high risk of recurrence is challenging. Radiological images can represent a source of data that can be analyzed by using automated computer-based techniques, working on numerical information coded within Digital Imaging and Communications in Medicine files: This image numerical analysis has been named "radiomics". Radiomics allows the extraction of quantitative features from radiological images, mainly invisible to the naked eye, that can be further analyzed by artificial intelligence algorithms. Radiomics is expanding in oncology to either understand tumor biology or for the development of imaging biomarkers for diagnosis, staging, and prognosis, prediction of treatment response and diseases monitoring and surveillance. Several efforts have been made to develop radiomics signatures for colorectal cancer patient using computed tomography (CT) images with different aims: The preoperative prediction of lymph node metastasis, detecting BRAF and RAS gene mutations. Moreover, the use of delta-radiomics allows the analysis of variations of the radiomics parameters extracted from CT scans performed at different timepoints. Most published studies concerning radiomics and magnetic resonance imaging (MRI) mainly focused on the response of advanced tumors that underwent neoadjuvant therapy. Nodes status is the main determinant of adjuvant chemotherapy. Therefore, several radiomics model based on MRI, especially on T2-weighted images and ADC maps, for the preoperative prediction of nodes metastasis in rectal cancer has been developed. Current studies mostly focused on the applications of radiomics in positron emission tomography/CT for the prediction of survival after curative surgical resection and assessment of response following neoadjuvant chemoradiotherapy. Since colorectal liver metastases develop in about 25% of patients with colorectal carcinoma, the main diagnostic tasks of radiomics should be the detection of synchronous and metachronous lesions. Radiomics could be an additional tool in clinical setting, especially in identifying patients with high-risk disease. Nevertheless, radiomics has numerous shortcomings that make daily use extremely difficult. Further studies are needed to assess performance of radiomics in stratifying patients with high-risk disease.
Keywords: Artificial intelligence; Colorectal cancer; Computed tomography; Liver metastases; Magnetic resonance imaging; Positron emission tomography/computed tomography; Radiomics.
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All the authors are aware of the content of the manuscript and have no conflict of interest.
Figures
Similar articles
-
Radiomics for the Prediction of Treatment Outcome and Survival in Patients With Colorectal Cancer: A Systematic Review.Clin Colorectal Cancer. 2021 Mar;20(1):52-71. doi: 10.1016/j.clcc.2020.11.001. Epub 2020 Nov 7. Clin Colorectal Cancer. 2021. PMID: 33349519
-
Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer.World J Gastroenterol. 2020 May 21;26(19):2388-2402. doi: 10.3748/wjg.v26.i19.2388. World J Gastroenterol. 2020. PMID: 32476800 Free PMC article.
-
Artificial intelligence for pre-operative lymph node staging in colorectal cancer: a systematic review and meta-analysis.BMC Cancer. 2021 Sep 26;21(1):1058. doi: 10.1186/s12885-021-08773-w. BMC Cancer. 2021. PMID: 34565338 Free PMC article.
-
MRI radiomics signature to predict lymph node metastasis after neoadjuvant chemoradiation therapy in locally advanced rectal cancer.Abdom Radiol (NY). 2023 Jul;48(7):2270-2283. doi: 10.1007/s00261-023-03910-4. Epub 2023 Apr 21. Abdom Radiol (NY). 2023. PMID: 37085730
-
MRI Radiomics Model Predicts Pathologic Complete Response of Rectal Cancer Following Chemoradiotherapy.Radiology. 2022 May;303(2):351-358. doi: 10.1148/radiol.211986. Epub 2022 Feb 8. Radiology. 2022. PMID: 35133200
Cited by
-
Imaging Assessment of the Response to Neoadjuvant Treatment in Rectal Cancer in Relation to Postoperative Pathological Outcomes.Curr Health Sci J. 2024 Oct-Dec;50(5):585-598. doi: 10.12865/CHSJ.50.04.13. Epub 2024 Dec 31. Curr Health Sci J. 2024. PMID: 40143884 Free PMC article.
-
CT-Based radiomics and deep learning for the preoperative prediction of peritoneal metastasis in ovarian cancers.Abdom Radiol (NY). 2025 Aug 13. doi: 10.1007/s00261-025-05162-w. Online ahead of print. Abdom Radiol (NY). 2025. PMID: 40802053
-
Research progress in multimodal radiomics of rectal cancer tumors and peritumoral regions in MRI.Abdom Radiol (NY). 2025 May 31. doi: 10.1007/s00261-025-04965-1. Online ahead of print. Abdom Radiol (NY). 2025. PMID: 40448847 Review.
-
Effectiveness of magnetic resonance imaging and spiral computed tomography in the staging and treatment prognosis of colorectal cancer.World J Gastrointest Surg. 2024 Jul 27;16(7):2135-2144. doi: 10.4240/wjgs.v16.i7.2135. World J Gastrointest Surg. 2024. PMID: 39087125 Free PMC article.
-
CT-based radiomics features for the differential diagnosis of nodular goiter and papillary thyroid carcinoma: an analysis employing propensity score matching.Front Oncol. 2024 Dec 12;14:1465941. doi: 10.3389/fonc.2024.1465941. eCollection 2024. Front Oncol. 2024. PMID: 39726704 Free PMC article.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin . 2021;71:209–249. - PubMed
-
- Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P, Yoshino T, Taieb J, Martinelli E, Arnold D ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol . 2020;31:1291–1305. - PubMed
-
- Weiser MR. AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol . 2018;25:1454–1455. - PubMed
-
- Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol . 2022;40:892–910. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials